ZyVersa Therapeutics (NASDAQ:ZVSA – Get Free Report) and Arcus Biosciences (NYSE:RCUS – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.
Risk & Volatility
ZyVersa Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for ZyVersa Therapeutics and Arcus Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ZyVersa Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Arcus Biosciences | 1 | 3 | 7 | 1 | 2.67 |
Insider & Institutional Ownership
3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares ZyVersa Therapeutics and Arcus Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ZyVersa Therapeutics | N/A | -109.54% | -43.95% |
| Arcus Biosciences | -142.91% | -65.77% | -32.51% |
Valuation & Earnings
This table compares ZyVersa Therapeutics and Arcus Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ZyVersa Therapeutics | N/A | N/A | -$9.41 million | ($1.34) | -0.15 |
| Arcus Biosciences | $247.00 million | 11.31 | -$353.00 million | ($3.30) | -6.75 |
ZyVersa Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Arcus Biosciences beats ZyVersa Therapeutics on 10 of the 14 factors compared between the two stocks.
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
About Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
